7 results on '"Golfrè Andreasi, Nico"'
Search Results
2. Focused ultrasound therapy in movement disorders: management roadmap toward optimal pathway organization.
- Author
-
Rinaldo, Sara, Cilia, Roberto, Leta, Valentina, Gammone, Mariarosaria, Golfrè Andreasi, Nico, Colucci, Fabiana, Braccia, Arianna, Telese, Roberta, Fusar Poli, Marco, Levi, Vincenzo, Antonio Romito, Luigi Michele, Ghilemetti, Francesco, De Martin, Elena, Fumagalli, Maria Luisa, Epifani, Francesca, Prioni, Sara, Amami, Paolo, Piacentini, Sylvie, Elia, Antonio Emanuele, and Devigili, Grazia
- Subjects
MOVEMENT disorders ,MOVEMENT therapy ,PARKINSON'S disease ,ESSENTIAL tremor ,GLOBUS pallidus - Abstract
MRI-guided focused ultrasound (MRgFUS) lesioning is an innovative, safe and effective treatment which provides an innovative development in the field of minimally invasive stereotactic neurosurgery. Based on the application of focused ultrasound energy under full MR planning and thermal imaging control, unilateral lesioning of the thalamus, subthalamic nucleus, and globus pallidus is indicated for the treatment of movement disorders, including essential tremor, Parkinson's disease, and dystonia. We started to apply this technique in February 2019 for the treatment of patients with movement disorders. The authors developed a diagnostic therapeutic care pathway, which is herewith proposed and applied as an explication of standard clinical practice in use. The project was the result of the application of different methods such as Health Technology Assessment (HTA), Strengths, Weaknesses, Opportunities and Threats analysis (SWOT) and Demin-Plan, Do, Check, Act (PDCA) cycle. The aim of this project was to standardize the MRgFUS diagnostic-therapeutic pathway (DTP), describe its application and the appropriateness of different phases (patient selection, intervention phase and follow-up). Here, we described in detail our experience in the DTP application from 2019 up to now in 610 patients with movement disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study.
- Author
-
Cilia, Roberto, Cereda, Emanuele, Piatti, Marco, Pilotto, Andrea, Magistrelli, Luca, Golfrè Andreasi, Nico, Bonvegna, Salvatore, Contaldi, Elena, Mancini, Francesca, Imbalzano, Gabriele, De Micco, Rosa, Colucci, Fabiana, Braccia, Arianna, Bellini, Gabriele, Brovelli, Francesco, Zangaglia, Roberta, Lazzeri, Giulia, Russillo, Maria Claudia, Olivola, Enrica, and Sorbera, Chiara
- Subjects
DOPA ,PARKINSON'S disease ,CASE-control method ,DISEASE duration ,MOVEMENT disorders ,DISEASE progression - Abstract
Background: Effects of dopaminergic medications used to treat Parkinson's disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (LED). However, current LED proposals on MAO‐B inhibitors (iMAO‐B) safinamide and rasagiline are still based on empirical approaches. Objectives: To estimate LED of safinamide 50 and 100 mg. Methods: In this multicenter, longitudinal, case–control study, we retrospectively reviewed clinical charts of 500 consecutive PD patients with motor complications and treated with (i) safinamide 100 mg (N = 130), safinamide 50 mg (N = 144), or rasagiline 1 mg (N = 97) for 9 ± 3 months and a control group of patients never treated with any iMAO‐B (N = 129). Results: Major baseline features (age, sex, disease duration and stage, severity of motor signs and motor complications) were similar among the groups. Patients on rasagiline had lower UPDRS‐II scores and Levodopa dose than control subjects. After a mean follow‐up of 8.8‐to‐10.1 months, patients on Safinamide 50 mg and 100 mg had lower UPDRS‐III and OFF‐related UPDRS‐IV scores than control subjects, who in turn had larger increase in total LED than the three iMAO‐B groups. After adjusting for age, disease duration, duration of follow‐up, baseline values and taking change in UPDRS‐III scores into account (sensitivity analysis), safinamide 100 mg corresponded to 125 mg LED, whereas safinamide 50 mg and rasagiline 1 mg equally corresponded to 100 mg LED. Conclusions: We used a rigorous approach to calculate LED of safinamide 50 and 100 mg. Large prospective pragmatic trials are needed to replicate our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Magnetic Resonance–Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early‐Stage Tremor‐Dominant Parkinson's Disease: A Pilot Study.
- Author
-
Golfrè Andreasi, Nico, Cilia, Roberto, Romito, Luigi Michele, Bonvegna, Salvatore, Straccia, Giulia, Elia, Antonio Emanuele, Novelli, Alessio, Messina, Giuseppe, Tringali, Giovanni, Levi, Vincenzo, Devigili, Grazia, Rinaldo, Sara, Gasparini, Valentina, Grisoli, Marina, Stanziano, Mario, Ghielmetti, Francesco, Prioni, Sara, Bocchi, Elisa, Amami, Paolo, and Piacentini, Sylvie Hélène Marie Jeanne
- Abstract
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is a safe and effective procedure for drug‐resistant tremor in Parkinson's disease (PD). Objective: The aim of this study was to demonstrate that MRgFUS ventralis intermedius thalamotomy in early‐stage tremor‐dominant PD may prevent an increase in dopaminergic medication 6 months after treatment compared with matched PD control subjects on standard medical therapy. Methods: We prospectively enrolled patients with early‐stage PD who underwent MRgFUS ventralis intermedius thalamotomy (PD‐FUS) and patients treated with oral dopaminergic therapy (PD‐ODT) with a 1:2 ratio. We collected demographic and clinical data at baseline and 6 and 12 months after thalamotomy. Results: We included 10 patients in the PD‐FUS group and 20 patients in the PD‐ODT group. We found a significant increase in total levodopa equivalent daily dose and levodopa plus monoamine oxidase B inhibitors dose in the PD‐ODT group 6 months after thalamotomy. Conclusions: In early‐stage tremor‐dominant PD, MRgFUS thalamotomy may be useful to reduce tremor and avoid the need to increase dopaminergic medications. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Resting State Functional Connectivity Signatures of MRgFUS Vim Thalamotomy in Parkinson's Disease: A Preliminary Study.
- Author
-
Stanziano, Mario, Golfrè Andreasi, Nico, Messina, Giuseppe, Rinaldo, Sara, Palermo, Sara, Verri, Mattia, Demichelis, Greta, Medina, Jean Paul, Ghielmetti, Francesco, Bonvegna, Salvatore, Nigri, Anna, Frazzetta, Giulia, D'Incerti, Ludovico, Tringali, Giovanni, DiMeco, Francesco, Eleopra, Roberto, and Bruzzone, Maria Grazia
- Subjects
TREMOR ,PARKINSON'S disease ,FUNCTIONAL connectivity ,HIGH-intensity focused ultrasound ,MOTOR cortex ,CEREBRAL hemispheres - Abstract
Magnetic Resonance-guided high-intensity Focused Ultrasound (MRgFUS) of the thalamic ventral intermediate nucleus (Vim) for tremor has increasingly gained interest as a new non-invasive alternative to standard neurosurgery. Resting state functional connectivity (rs-FC) correlates of MRgFUS have not been extensively investigated yet. A region of interest (ROI)-to-ROI rs-FC MRI "connectomic" analysis focusing on brain regions relevant for tremor was conducted on 15 tremor-dominant patients with Parkinson's disease who underwent MRgFUS. We tested whether rs-FC between tremor-related areas was modulated by MRgFUS at 1 and 3 months post-operatively, and whether such changes correlated with individual clinical outcomes assessed by the MDS-UPDRS-III sub items for tremor. Significant increase in FC was detected within bilateral primary motor (M1) cortices, as well as between bilateral M1 and crossed primary somatosensory cortices, and also between pallidum and the dentate nucleus of the untreated hemisphere. Correlation between disease duration and FC increase at 3 months was found between the putamen of both cerebral hemispheres and the Lobe VI of both cerebellar hemispheres, as well as between the Lobe VI of untreated cerebellar hemisphere with bilateral supplementary motor area (SMA). Drop-points value of MDS-UPDRS at 3 months correlated with post-treatment decrease in FC, between the anterior cingulate cortex and bilateral SMA, as well as between the Lobe VI of treated cerebellar hemisphere and the interpositus nucleus of untreated cerebellum. Tremor improvement at 3 months, expressed as percentage of intra-subject MDS-UPDRS changes, correlated with FC decrease between bilateral occipital fusiform gyrus and crossed Lobe VI and Vermis VI. Good responders (≥50% of baseline tremor improvement) showed reduced FC between bilateral SMA, between the interpositus nucleus of untreated cerebellum and the Lobe VI of treated cerebellum, as well as between the untreated SMA and the contralateral putamen. Good responders were characterized at baseline by crossed hypoconnectivity between bilateral putamen and M1, as well as between the putamen of the treated hemisphere and the contralateral SMA. We conclude that MRgFUS can effectively modulate brain FC within the tremor network. Such changes are associated with clinical outcome. The shifting mode of integration among the constituents of this network is, therefore, susceptible to external redirection despite the chronic nature of PD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Deep brain stimulation and refractory freezing of gait in Parkinson's disease: Improvement with high-frequency current steering co-stimulation of subthalamic nucleus and substantia Nigra.
- Author
-
Golfrè Andreasi, Nico, Rispoli, Vittorio, Contaldi, Elena, Colucci, Fabiana, Mongardi, Lorenzo, Cavallo, Michele Alessandro, and Sensi, Mariachiara
- Published
- 2020
- Full Text
- View/download PDF
7. Levodopa/Carbidopa Intestinal Gel Infusion Therapy: Focus on Gait and Balance.
- Author
-
Rispoli, Vittorio, Golfrè Andreasi, Nico, Penna, Giovanna, Contini, Eleonora, Sensi, Mariachiara, and Preda, Francesca
- Subjects
- *
DOPA , *CARBIDOPA , *BALANCE disorders , *QUALITY of life , *DAS-Naglieri Cognitive Assessment System - Abstract
Background: Gait and balance disorders in advanced Parkinson's disease (aPD) heavily impact the disease burden. In this prospective observational open‐label study, our aim was to evaluate the effectiveness of levodopa/carbidopa intestinal gel (LCIG) infusion on balance and gait over a long‐term follow‐up. Methods: The motor status of 15 aPD patients with balance and gait symptoms was assessed with UPDRS (I–IV) and H&Y at baseline in OFF and ON conditions, and after 52 weeks of LCIG infusion. Berg Balance Scale (BBS), Tinetti Gait & Balance Score (TS), Gait and Falls Questionnaire (G&F‐Q), FOG Questionnaire (FOG‐Q), and New FOG Questionnaire (NFOG‐Q) were used to specifically test balance and gait. Results: UPDRS, H&Y, BBS, TS, G&F‐Q, FOG‐Q, NFOG‐Q improved significantly. All FOG types benefited from LCIG. Conclusions: Our preliminary data show the beneficial effect of LCIG therapy not only on FOG, but also on gait and balance. Results need to be confirmed in larger cohort studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.